Physician biosimilar education — addressing prescriber concerns about biosimilar safety, switching consequences, and interchangeability — remains the most important demand-side factor in biosimilar market penetration, with the Biosimilars Market reflecting prescriber behavior as the critical adoption determinant beyond regulatory and pricing factors.

Biosimilar prescriber hesitancy sources — concerns about nocebo effects from patient apprehension, uncertainty about non-medical switching safety, perceived pharmacological differences between biosimilars and reference products, and limited time to discuss biosimilar transitions with patients — create psychological barriers to biosimilar prescribing that persist despite accumulated safety evidence. Surveys of US rheumatologists and gastroenterologists consistently show residual biosimilar prescribing hesitancy that educational interventions measurably reduce but do not eliminate.

ACR and AGA biosimilar position statements — American College of Rheumatology and American Gastroenterological Association endorsing biosimilar use and supporting non-medical switching based on evidence review — represent the specialty society guidance that has progressively moved professional consensus toward biosimilar acceptance. ACR's 2018 position statement supporting biosimilar use and switches when clinically appropriate provided the evidence-based framework that US rheumatologists reference for biosimilar prescribing decisions.

Patient biosimilar education programs — manufacturer-sponsored patient support programs providing biosimilar switching education, nurse educator support, and financial assistance — address patient-level biosimilar anxiety that nocebo-driven adverse reporting inflates. Patient education programs demonstrating comparable outcomes and addressing biosimilar science misconceptions improve patient acceptance of clinician-recommended biosimilar transitions.

Do you think specialty society position statements supporting biosimilar use have been sufficient to overcome prescriber hesitancy, or do individual patient outcome data at the clinician's own practice level ultimately drive biosimilar acceptance?

FAQ

Why are some physicians hesitant to prescribe biosimilars? Physician biosimilar hesitancy reflects concerns about: (1) nocebo effects from patient anxiety about switching, (2) safety of non-medical switching in patients with stable disease on reference biologic, (3) perceived immunogenicity or pharmacological differences that may not be captured in analytical testing, and (4) limited information about biosimilar manufacturing quality; accumulated real-world switching data has progressively addressed these concerns.

What do medical societies say about biosimilar switching? ACR, AGA, AAD, and other US specialty societies have issued position statements supporting biosimilar use and acknowledging that non-medical switching (switching for non-clinical reasons including cost) is supported by evidence from multiple randomized and observational studies; European societies including EULAR, ECCO, and EFAD have similar positions supporting switching based on extensive European real-world experience since 2006.

#BiosimilarsMarket #BiosimilarEducation #PhysicianBiosimilar #BiosimilarHesitancy #ACRbiosimilar #NoceboEffect